BioAro Launches AI‑Assisted LONgevity+ Bioactives In U.S. And U.K. Markets

BioAro launches AI‑assisted LONgevity+™ bioactives, now available in US and UK markets. The product line uses artificial intelligence to identify and optimize natural compounds aimed at supporting healthy aging. The company says AI reduces discovery time compared with traditional methods.

AI Assistance in the LONgevity+™ platform integrates machine‑learning models that screen thousands of molecular structures for safety and efficacy. BioAro reports the system can evaluate candidate compounds in weeks rather than months, accelerating the path to market for longevity supplements.

Industry Impact: The launch reflects growing adoption of AI in pharmaceutical research, echoed by recent conference on generative AI and drug discovery and other AI‑driven initiatives. Analysts note such AI‑enabled products could reshape supplement development and expand consumer access to scientifically backed longevity solutions.

Market Outlook: BioAro projects the LONgevity+™ line will capture a share of the $10 billion global anti‑aging supplement market within three years, leveraging AI to meet rising consumer demand for evidence‑based products.